Primary immune deficiency diseases are rare and genetic disorders, that are characterized by an impaired immune system. Some of the symptoms observed in the patients with these diseases are blood disorders, autoimmune disorders, recurrent pneumonia, inflammation of internal organs, and digestive problems. Primary immune deficiency diseases can occur due to B-cell deficiencies, T-cell deficiencies, defective phagocytes, combination of B- and T-cell deficiencies, and complement deficiencies. The only risk factor associated with this disease is family history. GigaGen Inc. is in the process of developing recombinant intravenous immunoglobulin (rIVIG) for the treatment of primary immune deficiency diseases. X4 Pharmaceuticals Inc. is in the process of developing X4P-001-RD as a CXCR4 receptor antagonist for the treatment this disease. Orchard Therapeutics Ltd. is also engaged in the pipeline for this disorder.
-
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
-
Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
